PT - JOURNAL ARTICLE AU - Aldridge, Chad M. AU - Robynne, Braun AU - Keene, Keith L. AU - Hsu, Fang-Chi AU - Sale, Michele M. AU - Worrall, Bradford B. TI - Post Stroke Motor Recovery Genome Wide Association Study: <em>A Domain-Specific Approach</em> AID - 10.1101/2023.02.16.23286040 DP - 2023 Jan 01 TA - medRxiv PG - 2023.02.16.23286040 4099 - http://medrxiv.org/content/early/2023/02/17/2023.02.16.23286040.short 4100 - http://medrxiv.org/content/early/2023/02/17/2023.02.16.23286040.full AB - Background In this genome wide association study (GWAS) we aimed to discover single nucleotide polymorphisms (SNPs) associated with motor recovery post-stroke.Methods We used the Vitamin Intervention for Stroke Prevention (VISP) dataset of 2,100 genotyped patients with non-disabling stroke. Of these, 488 patients had motor impairment at enrollment. Genotyped data underwent strict quality control and imputation. The GWAS utilized logistic regression models with generalized estimating equations (GEE) to leverage the repeated NIH Stroke Scale (NIHSS) motor score measurements spanning 6 time points over 24 months. The primary outcome was a decrease in the motor drift score of ≥ 1 vs. &lt; 1 at each timepoint. Our model estimated the odds ratio of motor improvement for each SNP after adjusting for age, sex, race, days from stroke to visit, initial motor score, VISP treatment arm, and principal components.Results Although no associations reached genome-wide significance (p &lt; 5 × 10−8), our analysis detected 115 suggestive associations (p &lt; 5 × 10−6). Notably, we found multiple SNP clusters near genes with plausible neuronal repair biology mechanisms. The CLDN23 gene had the most convincing association which affects blood-brain barrier integrity, neurodevelopment, and immune cell transmigration.Conclusion We identified novel suggestive genetic associations with the first ever motor-specific post stroke recovery GWAS. The results seem to describe a distinct stroke recovery phenotype compared to prior genetic stroke outcome studies that use outcome measures, like the mRS. Replication and further mechanistic investigation are warranted. Additionally, this study demonstrated a proof-of-principle approach to optimize statistical efficiency with longitudinal datasets for genetic discovery.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe GWAS component of the VISP study was supported by the United States National Human Genome Research Institute (NHGRI), Grant U01 HG005160 (PI Michele Sale &amp; Bradford Worrall), as part of the Genomics and Randomized Trials Network (GARNET). Genotyping services were provided by the Johns Hopkins University Center for Inherited Disease Research (CIDR), which is fully funded through a federal contract from the NIH to the Johns Hopkins University. Assistance with data cleaning was provided by the GARNET Coordinating Center (U01 HG005157; PI Bruce S Weir). Study recruitment and collection of datasets for the VISP clinical trial were supported by an investigator-initiated research grant (R01 NS34447; PI James Toole) from the United States Public Health Service, NINDS, Bethesda, Maryland. Control data for comparison with European ancestry VISP stroke cases were obtained through the database of genotypes and phenotypes (dbGAP) High Density SNP Association Analysis of Melanoma: Case-Control and Outcomes Investigation (phs000187.v1.p1; R01CA100264, 3P50CA093459, 5P50CA097007, 5R01ES011740, 5R01CA133996, HHSN268200782096C; PIs Christopher 300 Amos, Qingyi Wei, Jeffrey E. Lee). For VISP stroke cases of African ancestry, a subset of the Healthy Aging in Neighborhoods of Diversity across the Life Span study (HANDLS) were used as stroke free controls. HANDLS is funded by the National Institute of Aging (1Z01AG000513; PI Michele K. Evans).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the internal review boards (IRBs) of Wake Forest University School of Medicine, University of North Carolina at Chapel Hill School of Medicine as well as individual recruiting sites in accordance with the declaration of Helsinki. All patients provided written informed consent [12]. However, ten sites did not approve the genetic portion of the study resulting in 2,100 genotyped patients.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript